MetaCap

Dyne Therapeutics (DYN) vs Legend Biotech (LEGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dyne Therapeutics (DYN) has outperformed Legend Biotech (LEGN) over the past year, losing 26.8% versus a loss of 45.9%. Over five years, DYN leads with a +5.4% price change compared with -71.8% for LEGN. Legend Biotech is the larger company by market cap ($2.96 billion vs $2.90 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DYN-26.82%LEGN-45.86%
+33%-9%-50%
Nov 21, 20251 yearNov 20, 2026
DYN-1.84%LEGN-72.40%
+208%+61%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DYN versus LEGN key metrics
MetricDYNLEGN
Share price$15.50$15.25
Market cap$2.90B$2.96B
1-day change-3.31%-5.28%
YTD return-20.76%-29.85%
1-year return-26.82%-45.86%
5-year return+5.37%-71.83%
Forward P/E—28.89
EPS (TTM)$-3.62$-0.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.03B
Revenue growth (YoY)—+64.04%
Net income (latest FY)$-446.21M$-296.80M
Gross margin—61.41%
Operating margin—-13.27%
Net margin—-28.85%
52-week high$27.31$37.50
52-week low$14.00$15.15
Distance from 52-week high-43.23%-59.33%
Analyst consensusstrong_buybuy
Avg. price target upside+121.48%+168.39%
Average volume2.94M2.26M
Shares outstanding187.39M193.97M
Employees3223,300
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DYN has outperformed LEGN by 19.0 percentage points over the past year.

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

About Legend Biotech

LEGN stock →

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).

Health Care · Biotechnology: Pharmaceutical Preparations · 3,300 employees

DYN vs LEGN FAQ

Which is bigger, Dyne Therapeutics or Legend Biotech?

Legend Biotech (LEGN) is larger, with a market capitalization of $2.96B compared with $2.90B for Dyne Therapeutics (DYN).

Which stock has performed better over the past year, DYN or LEGN?

DYN returned -26.82% over the past 12 months, compared with -45.86% for LEGN (price return, excluding dividends). Past performance does not predict future results.

Are Dyne Therapeutics and Legend Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons